BridgeBio Pharma Total Long-Term Assets 2018-2024 | BBIO
BridgeBio Pharma total long-term assets from 2018 to 2024. Total long-term assets can be defined as the sum of all assets classified as non-current
BridgeBio Pharma Annual Total Long-Term Assets
(Millions of US $) |
| 2023 |
$69 |
| 2022 |
$74 |
| 2021 |
$124 |
| 2020 |
$61 |
| 2019 |
$63 |
| 2018 |
$20 |
| 2017 |
$ |
BridgeBio Pharma Quarterly Total Long-Term Assets
(Millions of US $) |
| 2024-09-30 |
$220 |
| 2024-06-30 |
$178 |
| 2024-03-31 |
$66 |
| 2023-12-31 |
$69 |
| 2023-09-30 |
$67 |
| 2023-06-30 |
$71 |
| 2023-03-31 |
$73 |
| 2022-12-31 |
$74 |
| 2022-09-30 |
$87 |
| 2022-06-30 |
$91 |
| 2022-03-31 |
$97 |
| 2021-12-31 |
$124 |
| 2021-09-30 |
$142 |
| 2021-06-30 |
$172 |
| 2021-03-31 |
$148 |
| 2020-12-31 |
$61 |
| 2020-09-30 |
$42 |
| 2020-06-30 |
$43 |
| 2020-03-31 |
$65 |
| 2019-12-31 |
$63 |
| 2019-09-30 |
$82 |
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.260B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
